Clinical Research Directory

Inclusion Criteria: * Provide written informed consent to participate in the trial according to ICH GCP (R3) and national/local regulations. * Diagnosed with liver cirrhosis for at least 6 months * Has a current Child-Pugh score ≤6 (Child A - clinically and biochemically compensated cirrhosis) * Has been participating in ultrasound or non-ultrasound (computed tomography (CT) or magnetic resonance imaging (MRI)) based surveillance for at least 6 months prior to entry. * Has not had any focal lesions, other than haemangiomas, detected during the past 6 months. Exclusion Criteria: * Any of the following: * autoimmune liver disease. * primary biliary cholangitis. * primary sclerosing cholangitis. * prior HCC * alcohol consumption \>3 standard drinks per day in men and 2 standard drinks per day in women. * currently taking a nonsteroidal anti-inflammatory drug, anticoagulant drugs, non-vitamin K anticoagulant frugs, or other antiplatelet drugs, including aspirin, within the last 6 months. * a known bleeding disorder * a platelet count \<50 x 109/L. * known history or endoscopic evidence of high risk oesophageal (grade 2 or higher) or gastric varices or, a history of bleeding varices. * chronic iron deficiency anaemia. * a prior history of liver decompensation or liver transplantation. * known peptic ulcer disease. * chronic kidney disease with eGFR \<50ml/min; a contraindication to aspirin. * Any participant considered by the PI to be deemed unlikely to complete the study due to other comorbid conditions or poor compliance will also be excluded. Pregnancy: * Whilst low dose aspirin is considered safe in pregnancy, male and female participants of child-bearing potential are recommended use effective contraception during this trial. * Any female participants who fall pregnant during the trial will be withdrawn if their treating obstetric doctor advises that you should do so.